SLC67A1 and central nervous system cancer: To evaluate the correlation between the SLC22A18 expression and the biological characteristics of glioma, SLC22A18 protein expression was compared in 30 patients with high grade (WHO III-IV) glioma and another 30 patients with low grade (WHO I-II) gliomas.